Companies › Calcilytix Therapeutics, Inc., a BridgeBio company
1 active drug program in 3 registered trials: 2 Phase 3, 1 Phase 2; Metabolic and endocrine; next expected readout Jan 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Encaleret Calcimimetic agent; allosteric activator of the calcium-sensing receptor (CaSR) | CASR | Phase 3 | Hypoparathyroidism; Autosomal Dominant Hypocalcemia (ADH); Autosomal Dominant Hypocalcemia Type 1 (ADH1) | Jan 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07805356 | Encaleret | Phase 3 | Hypoparathyroidism | Metabolic and endocrine | Jan 2028 |
| NCT07080385 | Encaleret | Phase 2 | Autosomal Dominant Hypocalcemia Type 1 (ADH1) | Metabolic and endocrine | Dec 2028 |
| NCT05680818 | Encaleret | Phase 3 | Autosomal Dominant Hypocalcemia (ADH) | Metabolic and endocrine | Aug 2029 |
Cash and short-term investments of $1.5bn on 2026-09-30; operating cash outflow about $419m a year; runway about 44 months at that burn, to May 2030; 3 of 3 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
vTv Therapeutics Medicure BrightGene New Bio-Medical Technology(Wuxi) Co.Ltd. Xintian Pharmaceutical Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.